161 related articles for article (PubMed ID: 23402268)
1. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.
Sasse S; Rothe A; Goergen H; Eichenauer DA; Lohri A; Kreher S; Jäger U; Bangard C; Kuhnert G; Böll B; von Tresckow B; Engert A
Leuk Lymphoma; 2013 Oct; 54(10):2144-8. PubMed ID: 23402268
[TBL] [Abstract][Full Text] [Related]
2. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
Driessen J; de Wit F; Herrera AF; Zinzani PL; LaCasce AS; Cole PD; Moskowitz CH; García-Sanz R; Fuchs M; Müller H; Borchmann P; Santoro A; Schöder H; Zijlstra JM; Hutten BA; Moskowitz AJ; Kersten MJ
Blood Adv; 2024 Jun; 8(11):2740-2752. PubMed ID: 38502227
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
5. Relapsed Hodgkin lymphoma: management strategies.
Montanari F; Diefenbach C
Curr Hematol Malig Rep; 2014 Sep; 9(3):284-93. PubMed ID: 24942298
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
Chen R; Palmer JM; Tsai NC; Thomas SH; Siddiqi T; Popplewell L; Farol L; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1864-8. PubMed ID: 25008328
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.
Federico M; Luminari S; Pellegrini C; Merli F; Pesce EA; Chauvie S; Gandolfi L; Capodanno I; Salati M; Argnani L; Zinzani PL
Haematologica; 2016 Apr; 101(4):e139-41. PubMed ID: 26703964
[No Abstract] [Full Text] [Related]
8. Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Santoro A; Moskowitz AJ; Ferrari S; Carlo-Stella C; Lisano J; Francis S; Wen R; Akyol A; Savage KJ
Blood; 2023 Jun; 141(22):2780-2783. PubMed ID: 36898084
[No Abstract] [Full Text] [Related]
9. Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.
Furtado M; Rule S
Clin Med Insights Oncol; 2012; 6():31-9. PubMed ID: 22253553
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Ramchandren R
Oncologist; 2012; 17(3):367-76. PubMed ID: 22387318
[TBL] [Abstract][Full Text] [Related]
11. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM; Schöder H; Johnson JL; Jung SH; Bartlett NL; Cheson BD;
Leuk Lymphoma; 2013 Jul; 54(7):1405-10. PubMed ID: 23194022
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Renaud L; Wencel J; Pagès A; Al Jijakli A; Moatti H; Quero L; Camus V; Brice P
Haematologica; 2024 May; ():. PubMed ID: 38695142
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Onishi M; Graf SA; Holmberg L; Behnia S; Shustov AR; Schiavo K; Philip M; Libby EN; Cassaday RD; Pagel JM; Roden JE; Maloney DG; Green DJ; Till BG; Press OW; Smith SD; Gopal AK
Hematol Oncol; 2015 Dec; 33(4):187-91. PubMed ID: 25236531
[TBL] [Abstract][Full Text] [Related]
14. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Gopal AK; Chen R; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Chi X; Sievers EL; Younes A
Blood; 2015 Feb; 125(8):1236-43. PubMed ID: 25533035
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
17. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
Horwitz SM; Advani RH; Bartlett NL; Jacobsen ED; Sharman JP; O'Connor OA; Siddiqi T; Kennedy DA; Oki Y
Blood; 2014 May; 123(20):3095-100. PubMed ID: 24652992
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.
Zinzani PL; Viviani S; Anastasia A; Vitolo U; Luminari S; Zaja F; Corradini P; Spina M; Brusamolino E; Gianni AM; Santoro A; Botto B; Derenzini E; Pellegrini C; Argnani L
Haematologica; 2013 Aug; 98(8):1232-6. PubMed ID: 23645687
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
Salihoglu A; Elverdi T; Karadogan I; Paydas S; Ozdemir E; Erdem G; Karadurmus N; Akyol G; Kaynar L; Yegin Z; Sucak G; Ozkocaman V; Topcuoglu P; Ozcan M; Birtas E; Goker H; Baslar Z; Ferhanoglu B
Ann Hematol; 2015 Mar; 94(3):415-20. PubMed ID: 25231929
[TBL] [Abstract][Full Text] [Related]
20. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
